(Applicant's Description) This application requests renewal of the Cancer Center Support Grant (CCSG) of the NCI-designated Comprehensive Cancer Center (CCC) of Metropolitan Detroit at Wayne State University. The Programs of the CCC reflect the cancer needs of the greater Metropolitan Detroit area. This is an industrialized, urban and ethnically diverse community with a disproportionate number of medically disadvantaged, low socio-economic citizens. This CCC has a long-standing and extensive community network dedicated to the prevention, earlier detection and treatment of cancer, particularly of urban minority, African American and Arab American populations which experience disproportionate mortality from breast, prostate and aerodigestive cancers. Our grant requests support for six research programs, ten core facilities, and related administrative activity. The CCC's established cancer research programs are Breast Cancer; Developmental Therapeutics; Molecular Biology and Genetics; Population Studies and Prevention; Prostate Cancer; and Proteases. CCSG support is also requested for Cores in Biostatistics, Clinical Trials, Cell Resources, Genetics/Genomics, Human Tissues and Pathology, Confocal Microscopy, Flow Cytometry, Nutrition, Community-Based Research Management and Pharmacology. Our Programs are organized to integrate basic, translational, and clinical research with population research-based, cancer control activities. An asset of our Center is our Metropolitan Detroit Cancer Surveillance System, a member of the NCI-sponsored SEER registry system. The programs represent focused and targeted research efforts aimed at addressing the special and unique characteristics and needs of cancer patients in our community and region. During the grant period, particular emphasis is to be placed on research issues related to the early events in breast cancer, on development of prevention research in breast, prostate and lung cancer, on the translation of that research into the community, and on the development of novel therapeutic approaches to these high-morbidity and mortality cancers. In addition, strong basic research efforts in molecular genetics and in understanding mechanisms of invasion and metastasis will be foundations for both clinical and community-based research. The CCC will continue to foster multidisciplinary interactions and collaborations, and to utilize CCSG developmental funds and other support to recruit new investigators and to develop translational research programs that have a high potential for peer- reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA022453-23S2
Application #
6894874
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1988-04-01
Project End
2005-03-31
Budget Start
2001-12-01
Budget End
2005-03-31
Support Year
23
Fiscal Year
2004
Total Cost
$500,000
Indirect Cost
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :
Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :
Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008
Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017
Saadat, Nadia; Liu, Fangchao; Haynes, Brittany et al. (2018) Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy. Mol Cancer Ther 17:2586-2597
Cheriyan, Vino T; Alsaab, Hashem; Sekhar, Sreeja et al. (2018) A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget 9:29680-29697
Burl, Rayanne B; Ramseyer, Vanesa D; Rondini, Elizabeth A et al. (2018) Deconstructing Adipogenesis Induced by ?3-Adrenergic Receptor Activation with Single-Cell Expression Profiling. Cell Metab 28:300-309.e4
Dedigama-Arachchige, Pavithra M; Acharige, Nuwan P N; Pflum, Mary Kay H (2018) Identification of PP1-Gadd34 substrates involved in the unfolded protein response using K-BIPS, a method for phosphatase substrate identification. Mol Omics 14:121-133

Showing the most recent 10 out of 826 publications